Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilucoplan in Pediatric Study Participants With Generalized Myasthenia Gravis
NCT06055959Phase 3Recruiting
- Sponsor
- UCB
- Start
- Oct 2024
- Primary completion
- Nov 2026
- Modality
- Cyclic Peptides
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of zilucoplan in myasthenia gravis (MG), sponsored by UCB. Primary endpoints: Plasma concentrations of zilucoplan at 4 weeks, Change from Baseline in sheep red blood cell lysis at 4 weeks and 1 more. Started Oct 2024; status: recruiting.
02
Drugs
zilucoplan
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06055959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06055959.